Description

Stevanato Group Ramps Fishers & Latina Capacity—The Make-or-Break Efficiency Story for 2026!

Stevanato Group delivered third quarter 2025 results that reflected strong execution in its core drug containment business alongside continued weakness in the Engineering segment. Revenue rose 9% year over year to $303.2 million, supported by 14% growth in the BDS segment that more than offset a 19% decline in Engineering. Performance benefited from shipment timing in BDS, with approximately $10 million of product shipments moved into the quarter to meet customer supply chain needs, largely within high-value solutions. High-value solutions revenue increased 47% and represented about half of total company revenue, driven primarily by demand for Nexa syringes and an improving trend in EZ-fill vials as vial destocking effects continued to abate. Margin performance improved, led by mix and early operating leverage from scale-up investments. Consolidated gross margin increased to 29.2%, and adjusted operating margin rose to 18.